Olutasidenib
Olutasidenib Phase 1/2 (glioma cohort)
Rigel · Phase 1/2 · Completed · Enrollment 93
| Arm | Population | Dose | Estimand | Comparator | Efficacy |
|---|---|---|---|---|---|
| Olutasidenib 150 mg BID | relapsed or refractory IDH1-mutant glioma (26 enrolled, 25 evaluable) | 150 mg | Single arm | n/r | objective response rate: 8%, 2 of 25disease control rate: 48%, 12 of 25 |